| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3ba6f026ef5776ed3a79d2944f81a87 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-01 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H13-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H13-02 |
| filingDate |
1998-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88e9d5e9bbf99677e439ba0e7ca26135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c82d2af6e9bc0073ca3bea5e8a0dfa6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f776beb2db5dee2b009a2db3cb87743 |
| publicationDate |
2000-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2348928-A1 |
| titleOfInvention |
Lps with reduced toxicity from genetically modified gram negative bacteria |
| abstract |
The subject invention lies in the field of vaccines. Specifically new compounds that can be used as adjuvants are provided. Recombinant LPS having a reduced number of secondary acyl chains per molecule of LPS vis a vis the corre-sponding non modified LPS molecule, said sec-ondary acyl chains being bound to primary acyl chains, said primary acyl chains being bound to the glucosamine of said recombinant LPS mol-ecule, said recombinant LPS being homogenous in acylation pattern is an example of such a com-pound. Also recombinant LPS having a phos-phate group attached to the glucosamine at the non reducing end of the LPS molecule and a phosphate group attached to the glucosamine at the reducing end of the molecule per recombi-nant LPS molecule provides a further example. |
| priorityDate |
1998-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |